Literature DB >> 14694136

High fidelity of yellow fever virus RNA polymerase.

Konstantin V Pugachev1, Farshad Guirakhoo, Simeon W Ocran, Fred Mitchell, Megan Parsons, Caroline Penal, Soheila Girakhoo, Svetlana O Pougatcheva, Juan Arroyo, Dennis W Trent, Thomas P Monath.   

Abstract

Three consecutive plaque purifications of four chimeric yellow fever virus-dengue virus (ChimeriVax-DEN) vaccine candidates against dengue virus types 1 to 4 were performed. The genome of each candidate was sequenced by the consensus approach after plaque purification and additional passages in cell culture. Our data suggest that the nucleotide sequence error rate for SP6 RNA polymerase used in the in vitro transcription step to initiate virus replication was as high as 1.34 x 10(-4) per copied nucleotide and that the error rate of the yellow fever virus RNA polymerase employed by the chimeras for genome replication in infected cells was as low as 1.9 x 10(-7) to 2.3 x 10(-7). Clustering of beneficial mutations that accumulated after multiple virus passages suggests that the N-terminal part of the prM protein, a specific site in the middle of the E protein, and the NS4B protein may be essential for nucleocapsid-envelope interaction during flavivirus assembly.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694136      PMCID: PMC368746          DOI: 10.1128/jvi.78.2.1032-1038.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Heterogeneous nature of the genome of the ARILVAX yellow fever 17D vaccine revealed by consensus sequencing.

Authors:  Konstantin V Pugachev; Simeon W Ocran; Farshad Guirakhoo; Dean Furby; Thomas P Monath
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

2.  Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa.

Authors:  J P Mutebi; H Wang; L Li; J E Bryant; A D Barrett
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence.

Authors:  Regina M Kofler; Franz X Heinz; Christian W Mandl
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

Authors:  Richard J Kuhn; Wei Zhang; Michael G Rossmann; Sergei V Pletnev; Jeroen Corver; Edith Lenches; Christopher T Jones; Suchetana Mukhopadhyay; Paul R Chipman; Ellen G Strauss; Timothy S Baker; James H Strauss
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

5.  Misincorporation by wild-type and mutant T7 RNA polymerases: identification of interactions that reduce misincorporation rates by stabilizing the catalytically incompetent open conformation.

Authors:  J Huang; L G Brieba; R Sousa
Journal:  Biochemistry       Date:  2000-09-26       Impact factor: 3.162

6.  Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo.

Authors:  C W Mandl; H Kroschewski; S L Allison; R Kofler; H Holzmann; T Meixner; F X Heinz
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

Authors:  Thomas P Monath; Karen McCarthy; Philip Bedford; Casey T Johnson; Richard Nichols; Sutee Yoksan; Ron Marchesani; Michael Knauber; Keith H Wells; Juan Arroyo; Farshad Guirakhoo
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

Review 8.  Flavivirus genome organization, expression, and replication.

Authors:  T J Chambers; C S Hahn; R Galler; C M Rice
Journal:  Annu Rev Microbiol       Date:  1990       Impact factor: 15.500

9.  Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Authors:  F Guirakhoo; J Arroyo; K V Pugachev; C Miller; Z X Zhang; R Weltzin; K Georgakopoulos; J Catalan; S Ocran; K Soike; M Ratterree; T P Monath
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

10.  Cleavage at a novel site in the NS4A region by the yellow fever virus NS2B-3 proteinase is a prerequisite for processing at the downstream 4A/4B signalase site.

Authors:  C Lin; S M Amberg; T J Chambers; C M Rice
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

View more
  45 in total

1.  The rate and spectrum of spontaneous mutations in a plant RNA virus.

Authors:  Nicolas Tromas; Santiago F Elena
Journal:  Genetics       Date:  2010-05-03       Impact factor: 4.562

Review 2.  The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins; Dave Jackson; Tyler Williamson
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

3.  The cost of replication fidelity in an RNA virus.

Authors:  Victoria Furió; Andrés Moya; Rafael Sanjuán
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

4.  Construction and mutagenesis of an artificial bicistronic tick-borne encephalitis virus genome reveals an essential function of the second transmembrane region of protein e in flavivirus assembly.

Authors:  Klaus K Orlinger; Verena M Hoenninger; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

5.  Use of sindbis/eastern equine encephalitis chimeric viruses in plaque reduction neutralization tests for arboviral disease diagnostics.

Authors:  B W Johnson; O Kosoy; E Wang; M Delorey; B Russell; R A Bowen; S C Weaver
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

6.  Populations of genomic RNAs devoted to the replication or spread of a bipartite plant virus differ in genetic structure.

Authors:  Gloria Lozano; Ana Grande-Pérez; Jesús Navas-Castillo
Journal:  J Virol       Date:  2009-09-30       Impact factor: 5.103

7.  Structure-function relationships underlying the replication fidelity of viral RNA-dependent RNA polymerases.

Authors:  Grace Campagnola; Seth McDonald; Stéphanie Beaucourt; Marco Vignuzzi; Olve B Peersen
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

8.  A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.

Authors:  F Guirakhoo; Z Zhang; G Myers; B W Johnson; K Pugachev; R Nichols; N Brown; I Levenbook; K Draper; S Cyrek; J Lang; C Fournier; B Barrere; S Delagrave; T P Monath
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Authors:  F Guirakhoo; K Pugachev; Z Zhang; G Myers; I Levenbook; K Draper; J Lang; S Ocran; F Mitchell; M Parsons; N Brown; S Brandler; C Fournier; B Barrere; F Rizvi; A Travassos; R Nichols; D Trent; T Monath
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Yellow fever virus exhibits slower evolutionary dynamics than dengue virus.

Authors:  Amadou A Sall; Ousmane Faye; Mawlouth Diallo; Cadhla Firth; Andrew Kitchen; Edward C Holmes
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.